You are here

Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

Last updated on April 11, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Cleveland, Ohio, 44195 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Familial Adenomatous Polyposis (FAP)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
12+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Celecoxib Treated Patients:

- Diagnosis of FAP based on the expression of the FAP phenotype.

- Celecoxib treatment prescribed outside of a clinical trial setting with expected
duration of celecoxib treatment of at least six months.

Historical/Concurrent Control Patients:

- Diagnosis of FAP based on the expression of the FAP phenotype.

- Be greater than or equal to 12 years old at the time of study enrollment.

- Have an endoscopically assessable colonic, rectal, ileal pouch and/or gastroduodenal
segment.

- For the group of post-surgical patients, IRA or IPAA performed from 1985 onward (in
order to assure standardized surgical techniques and post-surgical management).
Patients whose primary colorectal surgery was performed prior to 1985 will not be
eligible to serve as historical controls.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Celecoxib Treated Patients:

- Have received a pharmacological treatment (other than celecoxib) within the last 3
months for their FAP disease including treatment of any extracolonic manifestation of
FAP.

- Have received a non-steroidal anti-inflammatory drug (NSAID) within the last 3 months,
other than celecoxib, for any reason.

Historical/Concurrent Control Patients:

- Have pharmacological treatment recorded for their FAP disease at the defined index
date.

- Have received a non-steroidal anti-inflammatory drug (NSAID) within the last 3 months
for any reason.

NCT00151476
Pfizer
Terminated
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Familial Persistent Pulmonary Hypertension
NCT01720524
All Genders
0+
Years
Multiple Sites
Familial Adenomatous Polyposis (FAP)
NCT00151476
All Genders
12+
Years
Multiple Sites
Hypertension, Angina Pectoris, Hypercholesterolemia, Familial Hypercholesterolemia
NCT01107743
All Genders
Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP), Transthyretin Cardiomyopathy (TTR-CM), Familial Amyloid Cardiomyopathy, Senile Systemic Amyloidosis (SSA)
NCT01604122
All Genders
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
A Registry-Based Observational Study Assessing Clinical Outcomes In Familial Adenomatous Polyposis In Patients Receiving Celecoxib (Celebrex(Registered), Onsenal(Registered)) Compared With Control Patients

This is a registry-based observational study assessing clinical outcomes in FAP patients receiving celecoxib compared with historical/concurrent registry patients who have not received celecoxib.

Both retrospective and prospective data will be utilized. No sampling methods apply.

The study prematurely discontinued on April 11, 2008 due to slow enrollment. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.
Observational
Observational Model: Cohort
Not Provided
Not Provided
Non-Probability Sample
Patients with FAP
Familial Adenomatous Polyposis (FAP)
  • Drug: Celecoxib
    800 mg total daily dosing
    Other Name: celebrex, SC-58635
  • Other: Routine Medical Care
  • Celecoxib - Routine Medical Care
    800 mg total daily dosing
    Intervention: Drug: Celecoxib
  • Control Group - Routine Medical Care
    Observation of subjects treated with routine medical care
    Intervention: Other: Routine Medical Care
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
68
November 2008
November 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Celecoxib Treated Patients:

  • Diagnosis of FAP based on the expression of the FAP phenotype.
  • Celecoxib treatment prescribed outside of a clinical trial setting with expected duration of celecoxib treatment of at least six months.

Historical/Concurrent Control Patients:

  • Diagnosis of FAP based on the expression of the FAP phenotype.
  • Be greater than or equal to 12 years old at the time of study enrollment.
  • Have an endoscopically assessable colonic, rectal, ileal pouch and/or gastroduodenal segment.
  • For the group of post-surgical patients, IRA or IPAA performed from 1985 onward (in order to assure standardized surgical techniques and post-surgical management). Patients whose primary colorectal surgery was performed prior to 1985 will not be eligible to serve as historical controls.

Exclusion Criteria:

Celecoxib Treated Patients:

  • Have received a pharmacological treatment (other than celecoxib) within the last 3 months for their FAP disease including treatment of any extracolonic manifestation of FAP.
  • Have received a non-steroidal anti-inflammatory drug (NSAID) within the last 3 months, other than celecoxib, for any reason.

Historical/Concurrent Control Patients:

  • Have pharmacological treatment recorded for their FAP disease at the defined index date.
  • Have received a non-steroidal anti-inflammatory drug (NSAID) within the last 3 months for any reason.
Sexes Eligible for Study: All
12 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   Denmark,   Spain,   United States
Germany
 
NCT00151476
NQ4-00-02-012
A3191167
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer Inc
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2010

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now